27.44
2.31 (9.19%)
| Previous Close | 25.13 |
| Open | 25.27 |
| Volume | 1,269,740 |
| Avg. Volume (3M) | 2,577,900 |
| Market Cap | 2,775,886,080 |
| Price / Sales | 37.71 |
| Price / Book | 2.47 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -1,596.87% |
| Diluted EPS (TTM) | -4.61 |
| Quarterly Revenue Growth (YOY) | 0.80% |
| Total Debt/Equity (MRQ) | 14.08% |
| Current Ratio (MRQ) | 8.81 |
| Operating Cash Flow (TTM) | -351.38 M |
| Levered Free Cash Flow (TTM) | -185.90 M |
| Return on Assets (TTM) | -19.05% |
| Return on Equity (TTM) | -38.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Beam Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.22% |
| % Held by Institutions | 98.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management Llc | 30 Jun 2025 | 10,013,111 |
| Sumitomo Mitsui Trust Group, Inc. | 30 Jun 2025 | 4,729,444 |
| Nikko Asset Management Americas, Inc. | 30 Jun 2025 | 4,726,799 |
| Arch Venture Management, Llc | 30 Jun 2025 | 4,540,132 |
| Mwg Management Ltd. | 30 Jun 2025 | 2,266,934 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 191.55%) | Buy |
| Median | 50.50 (84.04%) | |
| Low | 21.00 (Barclays, -23.47%) | Hold |
| Average | 50.50 (84.04%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 19.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 Sep 2025 | 80.00 (191.55%) | Buy | 21.28 |
| Barclays | 06 Aug 2025 | 21.00 (-23.47%) | Hold | 18.30 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Aug 2025 | Announcement | Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |